Corey Davis
Stock Analyst at HC Wainwright & Co.
(2.94)
# 1,401
Out of 5,141 analysts
17
Total ratings
75%
Success rate
25.83%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Corey Davis
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| NKTR Nektar Therapeutics | Reiterates: Neutral | $480 → $390 | $73.73 | +428.96% | 5 | May 12, 2020 | |
| SCYX SCYNEXIS | Assumes: Buy | $50 | $0.78 | +6,277.55% | 3 | May 7, 2018 | |
| VTVT vTv Therapeutics | Downgrades: Neutral | $560 → $40 | $34.30 | +16.62% | 2 | Apr 10, 2018 | |
| LPCN Lipocine | Initiates: Buy | $170 | $9.80 | +1,634.69% | 1 | Mar 29, 2018 | |
| VNDA Vanda Pharmaceuticals | Initiates: Buy | $20 | $5.76 | +247.22% | 2 | Jan 19, 2018 | |
| PCRX Pacira BioSciences | Initiates: Buy | $50 | $23.22 | +115.33% | 3 | Jan 19, 2018 | |
| JAZZ Jazz Pharmaceuticals | Initiates: Neutral | $144 | $172.19 | -16.37% | 1 | Aug 25, 2017 |
Nektar Therapeutics
May 12, 2020
Reiterates: Neutral
Price Target: $480 → $390
Current: $73.73
Upside: +428.96%
SCYNEXIS
May 7, 2018
Assumes: Buy
Price Target: $50
Current: $0.78
Upside: +6,277.55%
vTv Therapeutics
Apr 10, 2018
Downgrades: Neutral
Price Target: $560 → $40
Current: $34.30
Upside: +16.62%
Lipocine
Mar 29, 2018
Initiates: Buy
Price Target: $170
Current: $9.80
Upside: +1,634.69%
Vanda Pharmaceuticals
Jan 19, 2018
Initiates: Buy
Price Target: $20
Current: $5.76
Upside: +247.22%
Pacira BioSciences
Jan 19, 2018
Initiates: Buy
Price Target: $50
Current: $23.22
Upside: +115.33%
Jazz Pharmaceuticals
Aug 25, 2017
Initiates: Neutral
Price Target: $144
Current: $172.19
Upside: -16.37%